Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity
暂无分享,去创建一个
B. Kuster | S. Lemeer | Anne-Kathrin Garz | K. Götze | F. Bassermann | M. Rudelius | C. Peschel | C. Haass | U. Germing | C. Langer | U. Keller | U. Platzbecker | S. Knop | Bettina Schmid | A. Knorn | M. Heider | H. Einsele | F. Bebber | R. Eichner | Vanesa Fernández-Sáiz | B. Targosz | Laura Jacobs | J. Slawska | Vanesa Fernández-Sáiz
[1] G. Petzold,et al. Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase , 2016, Nature.
[2] S. Carr,et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.
[3] G. Pinkus,et al. The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells , 2015, Nature Medicine.
[4] Aspire Investigators,et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .
[5] Michael L. Wang,et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.
[6] Neeraj Gupta,et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. , 2014, The Lancet. Oncology.
[7] A. Rosenwald,et al. Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis , 2014, Nature Medicine.
[8] B. Pégourié,et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Handa,et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.
[10] R. Fonseca,et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. , 2014, Blood.
[11] Jeremy L. Jenkins,et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.
[12] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[13] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[14] H. Handa,et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.
[15] R. Chopra,et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity , 2013, British journal of haematology.
[16] M. Pagano,et al. The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer. , 2014, Biochimica et biophysica acta.
[17] G. Mufti,et al. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes , 2013, Annals of Hematology.
[18] R. Johnstone,et al. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy , 2013, Oncogene.
[19] D. Jelinek,et al. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells , 2013, Cell cycle.
[20] J. Pouysségur,et al. Disrupting proton dynamics and energy metabolism for cancer therapy , 2013, Nature Reviews Cancer.
[21] Neil Vargesson,et al. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro , 2013, Proceedings of the National Academy of Sciences.
[22] K. Taskén,et al. CD147 in regulatory T cells. , 2013, Cellular immunology.
[23] E. Kremmer,et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth , 2013, Proceedings of the National Academy of Sciences.
[24] D. Sabatini,et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.
[25] Christian Langer,et al. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma , 2012, Nature Cell Biology.
[26] A. Dispenzieri,et al. Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation , 2012, Leukemia.
[27] P. L. Bergsagel,et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. , 2012, Blood.
[28] Shao-Chun Wang,et al. Epidermal Growth Factor Receptor Protects Proliferating Cell Nuclear Antigen from Cullin 4A Protein-mediated Proteolysis* , 2012, The Journal of Biological Chemistry.
[29] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[30] P. L. Bergsagel,et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.
[31] M. Cazzola,et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.
[32] J. Pouysségur,et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors , 2011, Proceedings of the National Academy of Sciences.
[33] Chul-Seung Park,et al. Functional modulation of AMP-activated protein kinase by cereblon. , 2011, Biochimica et biophysica acta.
[34] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.
[35] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[36] Y. Li,et al. Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation , 2010, Journal of cellular and molecular medicine.
[37] Michele Pagano,et al. The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint , 2008, Cell.
[38] H. Dombret,et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.
[39] M. Gordon. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .
[40] M. Greene,et al. CD147 immunoglobulin superfamily receptor function and role in pathology. , 2007, Experimental and molecular pathology.
[41] R. Roepman,et al. A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes , 2007, Proteomics.
[42] Pengbo Zhou,et al. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. , 2007, Molecular cell.
[43] M. MacCoss,et al. Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery , 2006, Nature.
[44] Chul-Seung Park,et al. Identification and functional characterization of cereblon as a binding protein for large‐conductance calcium‐activated potassium channel in rat brain , 2005, Journal of Neurochemistry.
[45] Yi Tang,et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. , 2005, Cancer research.
[46] D. Raible,et al. Zebrafish rx3 and mab21l2 are required during eye morphogenesis. , 2004, Developmental biology.
[47] Angus G. Dalgleish,et al. The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.
[48] G. Schütz,et al. Selective Inhibition of T Cell Activation Via CD147 Through Novel Modulation of Lipid Rafts1 , 2003, The Journal of Immunology.
[49] U. Germing,et al. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome , 2003, Leukemia.
[50] B. Zhivotovsky,et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. , 2003, Blood.
[51] P. Rameshwar,et al. Oxygen saturation in the bone marrow of healthy volunteers. , 2002, Blood.
[52] A. Barclay,et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression , 2000, The EMBO journal.
[53] T. Baker,et al. Lon and Clp family proteases and chaperones share homologous substrate-recognition domains. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[54] G. Mellin,et al. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. , 1962, The New England journal of medicine.